Get the Stockscreener App
1.51
7.86%
0.11
After Hours:
1.52
0.01
+0.66%
Dare Bioscience Inc stock is traded at $1.51, with a volume of 204.46K.
It is up +7.86% in the last 24 hours and down -9.58% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$1.40
Open:
$1.42
24h Volume:
204.46K
Relative Volume:
2.39
Market Cap:
$21.58M
Revenue:
$48,200
Net Income/Loss:
$-16.66M
P/E Ratio:
-0.8469
EPS:
-1.783
Net Cash Flow:
$-17.15M
1W Performance:
+16.15%
1M Performance:
-9.58%
6M Performance:
-27.75%
1Y Performance:
-47.57%
1-Day Range:
$1.3801
$1.61
1-Week Range:
$1.27
$1.61
52-Week Range:
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.51 | 20.00M | 48,200 | -16.66M | -17.15M | -1.783 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Dare Bioscience Inc Stock (DARE) Latest News
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency - Investing.com
Daré Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:DARE) 2026-03-26 - Seeking Alpha
Daré Bioscience (NASDAQ: DARE) expands dual-path women’s health model - Stock Titan
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Dare Bioscience Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
On National Viagra Day, Women Finally Claim Their Turn: - Yahoo! Finance Canada
Dare Bioscience (DARE) Expected to Announce Earnings on Monday - Defense World
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 - The Manila Times
Daré Bioscience, Inc. to Host Conference Call on March 26, 2026, for Year-End Financial Results and Company Update - Quiver Quantitative
Daré Bioscience schedules March 26 webcast for 2025 results - Stock Titan
DARE BIOSCIENCE, INC. Files Form 8-K with SEC Reporting Unregistered Sale of Equity Securities - Minichart
Dare Bioscience secures NIH funding extension for preterm birth therapy - MSN
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks
Daré Bioscience (DARE) issues 43,050 preferred-and-warrant units - Stock Titan
Daré Bioscience extends NIH grant period for preterm birth drug By Investing.com - Investing.com Australia
DARE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dare Bioscience (DARE) Advances Investigational Preterm Birth Tr - GuruFocus
Dare Bioscience receives NIH funding extension for preterm birth treatment By Investing.com - Investing.com Australia
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - The Manila Times
NIH funds hormone ring as preterm birth lacks FDA-approved treatment - Stock Titan
Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Sahm
Dare Bioscience Participates in Virtual Investor "What This Means" Segment - Bitget
Persistent HPV has no FDA-approved drug; Daré CEO lays out DARE-HPV trial plan - Stock Titan
Daré Bioscience Participates in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Completes Second Closing of Regulation A Offering - TipRanks
Daré Bioscience (NASDAQ: DARE) advances Regulation A unit offering - Stock Titan
Daré Bioscience Updates Investor Presentation Under Regulation FD - TipRanks
Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K - Stock Titan
DARE Should I Buy - Intellectia AI
DARE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Daré Bioscience gets FDA clearance for HPV treatment trial By Investing.com - Investing.com India
Daré Bioscience gets FDA clearance for HPV treatment trial - Investing.com Australia
Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Bitget
Daré Bioscience Announces FDA Clearance of IND for Phase 2 - GlobeNewswire
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - ChartMill
Dare Bioscience (DARE) CEO subscribes to Reg A units with warrants - Stock Titan
DARE SEC FilingsDare Bioscience Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dare Bioscience Launches Telehealth Consultations for Women's Arousal Cream - Intellectia AI
Dare Bioscience (DARE) Launches Telehealth for Topical Sildenafi - GuruFocus
First-of-its-kind arousal cream for women offers US-wide telehealth access - Stock Titan
Telehealth Now Available for DARE to PLAY™ Sildenafil - GlobeNewswire
Dare Bioscience Secures Strategic Autonomy with Key Asset Reversion - AD HOC NEWS
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com
Daré Bioscience Launches Regulation A Preferred Unit Offering - TipRanks
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Yahoo Finance
Dare Bioscience (NASDAQ:DARE) Share Price Passes Below 50-Day Moving Average – What’s Next? - Defense World
Daré Bioscience issues updated investor corporate presentation - MSN
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):